– USA, MA – CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced the appointment of Board Member Dr. Jon Talamo (M.D.) as its new Chair of the Board of Directors.
“With a career spanning ophthalmic surgery to therapeutic development and industry leadership, Jon brings a wealth of experience to our Board. We look forward to Jon’s leadership as CXLO strives to deliver safer and more accessible care globally to the millions of patients at risk of vision loss due to keratoconus,” said CEO Mike Webb.
About Dr. Jonathan Talamo
Dr. Jon Talamo, an ophthalmic surgeon with over 25 years in clinical practice, is a leader in corneal disease cataracts, and refractive surgery. After 25 years in the clinic, he pivoted to executive roles in biomedicine and healthcare. As CMO of Ocular Therapeutix, Dr. Talamo helped usher in the development of Dextenza for post-surgical inflammation and managed a pipeline of ophthalmologic therapeutics. In his subsequent role as CMO and Worldwide VP of Clinical and Medical Affairs at Johnson & Johnson Vision, Dr. Talamo helped lead the integration of Abbott Medical Optics and the global launch of multiple ophthalmologic products.
“I am thrilled to work more closely with the CXLO Board as we develop the minimally-invasive EpiSmart cross-linking system to improve patient comfort and preserve vision,” said Dr. Jon Talamo. “I look forward to collaborating with the CXLO team to improve safety and clinical outcomes for patients with keratoconus.”
About CXL Ophthalmics
CXLO is developing a minimally-invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
For more information: https://www.cxlophthalmics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.